Targeting alpha-3 glycine receptors for non-opioid pain relief
Peripheral and Central Pathways of α3 Glycine Receptors as Non-Opioid Molecular Targets to Treat Pain
['FUNDING_R01'] · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · NIH-11318982
Aiming to create a non-opioid medicine that boosts alpha-3 glycine receptors to reduce chronic nerve and inflammatory pain.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF PITTSBURGH AT PITTSBURGH (nih funded) |
| Locations | 1 site (PITTSBURGH, UNITED STATES) |
| Trial ID | NIH-11318982 on ClinicalTrials.gov |
What this research studies
From a patient's perspective, researchers are developing drugs that enhance alpha-3 glycine receptors, which help quiet pain signals in the spinal cord and midbrain. They combine studies of human receptor structures, electrical recordings from nerve cells, and animal tests to find molecules that boost these receptors without acting on opioid or psychotropic targets. A lead compound from this work relieved neuropathic and inflammatory pain in rodents and was more potent than morphine in those models. The long-term goal is to translate these findings into safer, non-addictive treatments for people with chronic nerve or inflammatory pain.
Who could benefit from this research
Good fit: Adults with chronic neuropathic or inflammatory pain who have not found adequate relief with current pain medicines could be candidates for future clinical trials.
Not a fit: People with short-term acute pain, pain not driven by neuropathic or inflammatory mechanisms, or those needing immediate rescue analgesia are unlikely to benefit from this approach.
Why it matters
Potential benefit: Could provide a non-opioid pain treatment that reduces neuropathic and inflammatory pain with lower risk of addiction and fewer psychoactive side effects.
How similar studies have performed: Preclinical studies of glycine receptor positive modulators, including the team's rodent experiments, show promising pain relief, but human trials of this specific approach have not yet been done.
Where this research is happening
PITTSBURGH, UNITED STATES
- UNIVERSITY OF PITTSBURGH AT PITTSBURGH — PITTSBURGH, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: XU, YAN — UNIVERSITY OF PITTSBURGH AT PITTSBURGH
- Study coordinator: XU, YAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.